<!doctype html>
<html class="no-js" lang="en">
  <head>
    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-55424252-12"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'UA-55424252-12');
    </script>
    <meta charset="utf-8">
    <meta http-equiv="x-ua-compatible" content="ie=edge">
    <title>RaQualia Pharma Pipeline [4579] - Ariafloat Stock</title>
    <meta name="description" content="RaQualia Pharma Pipeline [4579]">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link rel="icon" type="image/png" href="../../img/boundcat-icon.png">
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/css/bootstrap.min.css" integrity="sha384-PsH8R72JQ3SOdhVi3uxftmaW6Vc51MKb0q5P2rRUpPvrszuE4W1povHYgTpBfshb" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/normalize/7.0.0/normalize.min.css">
    <link rel="stylesheet" href="../../css/main.css">
    <link rel="stylesheet" href="../css/raqualia.css">
    <!-- Google AdSense -->
    <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
    <script>
      (adsbygoogle = window.adsbygoogle || []).push({
        google_ad_client: "ca-pub-6825342955400774",
        enable_page_level_ads: true
      });
    </script>
    <!-- Google AdSense  -->
  </head>
  <body id="top">
    <nav class="navbar navbar-expand-lg navbar-dark bg-dark">
      <div class="container">
        <a class="navbar-brand" href="https://stock.ariafloat.com/">Ariafloat Stock</a>
        <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
          <span class="navbar-toggler-icon"></span>
        </button>
        <div class="collapse navbar-collapse" id="navbarNav">
          <ul class="navbar-nav ml-md-auto">
            <li class="nav-item">
              <a class="nav-link" href="https://stock.ariafloat.com/raqualia/">Japanese</a>
            </li>
            <li class="nav-item">
              <a class="nav-link" href="https://stock.ariafloat.com/raqualia/en/">Top</a>
            </li>
          </ul>
        </div>
      </div>
    </nav>    
    <main role="main" style="text-align: center;">
      <h1 style="text-align: center; padding-top: 1rem;">RaQualia Pharma</h1>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 2rem;">
        <div class="container" style="max-width: 500px;">
          <table class="table table-bordered">
            <tbody>
              <tr>
                <th scope="row">Stock Market</th>
                <td>Tokyo Stock Exchange: Growth Market</td>
              </tr>
              <tr>
                <th scope="row">Security Code</th>
                <td>4579</td>
              </tr>
              <tr>
                <th scope="row">Website</th>
                <td><a href="https://www.raqualia.com/en/" target="_blank" rel="nofollow noopener" style="text-decoration: underline;">RaQualia Pharma Website</a></td>
              </tr>
            </tbody>
          </table>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem;">
        <div class="container">
          <h2 style="font-size: 1.7em">RaQualia Pharma Research Report</h2>
          <ul style=" max-width: 380px; margin: 0 auto; text-align: left;">
            <li><a href="https://www.raqualia.com/en/news/ir/ir5011815942269014525/main/0/link/4579_EN_20241008.pdf" target="_blank" rel="nofollow noopener">Shared Research Report [10/8, 2024]</a></li>
          </ul>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Pipelines</h2>
          <p>Updated on 1 6, 2025</p>
          <div class="pipeline-arrow-example-en">
            <div class="pipeline-arrow-end-legend-en">Completed</div>
            <div class="pipeline-arrow-prepared-legend-en">On planning</div>
            <div class="pipeline-arrow-legend-en">On going</div><div class="pipeline-arrow-example-clearboth"></div>
            <div class="pipeline-arrow-sale-legend-en">Launch</div>
            <div class="pipeline-arrow-plan-legend-en">Plan</div>
            <div style="clear: both;"></div>
          </div>
          <div class="scrollbooster-viewport-pipeline">
            <table class="table-simple table-pipeline scrollbooster-viewport-content-pipeline">
              <colgroup>
                <col span="1" style="width: 140px;">
                <col span="1" style="width: 117px;">
                <col span="1" style="width: 135px;">
                <col span="1" style="width: 110px;">
                <col span="8" style="width: 62px;">
                <col span="1" style="width: 75px;">
                <col span="1" style="width: 255px;">
              </colgroup>
              <thead>
                <tr>
                  <th rowspan="2">Program</th>
                  <th rowspan="2">Compound code<br>(Generic name)</th>
                  <th rowspan="2">Indication</th>
                  <th rowspan="2">Partnered party</th>
                  <th rowspan="2">Discovery</th>
                  <th rowspan="2">Pre-Clin,</th>
                  <th colspan="3">Clinical Trial</th>
                  <th rowspan="2">NDA</th>
                  <th rowspan="2">Approval</th>
                  <th rowspan="2">Launch</th>
                  <th rowspan="2">Territory</th>
                  <th rowspan="2">Remarks</th>
                </tr>
                <tr style="font-size: 0.9em;">
                  <th>Phase 1</th>
                  <th>Phase 2</th>
                  <th>Phase 3</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="12"><a href="https://stock.ariafloat.com/raqualia/pipeline/tegoprazan.html">Potassium-Competitive Acid Blocker<br>(P-CAB)</a></td>
                  <td rowspan="12">RQ-00000004<br>(Tegoprazan)<br>IN-12420 [HK inno.N]<br>LXI-15028 [Luoxin Pharma]<br>BLI5100 [Braintree Laboratories]</td>
                  <td rowspan="12">GERD<br>(ERD/NERD)<br>Gastric Ulcer<br>H. pylori Treatment</td>
                  <td>-</td>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td rowspan="11">HK inno.N</td>
                  <td colspan="5"><div class="pipeline-arrow">On going P3 (EE, NERD)</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option">Re-contracted: HK inno.N => Braintree Laboratories (Including Canada)</td>
                </tr>
                <tr>
                  <td colspan="8"><div class="pipeline-arrow-sale">Launch</div></td>
                  <td>Korea<br>China<br>Philippines<br>Mongolia<br>Mexico<br>Peru<br>Chile<br>Colombia<br>Dominican Republic<br>Nicaragua<br>Honduras<br>Guatemala<br>El Salvador<br>Indonesia<br>Singapore</td>
                  <td class="text-left pipeline-option">
                    [Korea]<br>
                    Product name: K-CAB<br>
                    ---<br>
                    [China]<br>
                    Product name: 泰欣赞<br>
                    Re-contracted: HK inno.N => Luoxin Pharma<br>
                    ---<br>
                    [Philippines]<br>
                    Re-contracted: HK inno.N => Metro Pharma Phils<br>
                    ---<br>
                    [Mongolia]<br>
                    Re-contracted: HK inno.N => Monos Pharma<br>
                    ---<br>
                    [Mexico, Peru, Chile, Colombia, Dominican Republic, Nicaragua, Honduras, Guatemala, El Salvador]<br>
                    Product name: Ki-CAB<br>
                    Re-contracted: HK inno.N => Laboratorios Carnot<br>
                    ---<br>
                    [Indonesia]<br>
                    Product name: TEZA<br>
                    Re-contracted: HK inno.N => Kalbe Farma<br>
                    ---<br>
                    [Singapore]<br>
                    Re-contracted: HK inno.N => United Italian Trading Corporation (UITC)
                  </td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Vietnam</td>
                  <td class="text-left pipeline-option">Re-contracted: HK inno.N => Lynh Pharma</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Thailand</td>
                  <td class="text-left pipeline-option">Re-contracted: HK inno.N => Pond's Chemical Thailand R.O.P.</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Malaysia</td>
                  <td class="text-left pipeline-option">Pharmaceutical supply contract: HK inno.N => Pharmaniaga Logistics</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Latin America<br>8 countries<br>(Argentina etc.)</td>
                  <td class="text-left pipeline-option">Re-contracted: HK inno.N => Laboratorios Carnot</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Brazil</td>
                  <td class="text-left pipeline-option">Re-contracted: HK inno.N => Eurofarma Laboratórios S.A.</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>India<br>South Africa<br>Asia and Eastern Europe: 5 countries</td>
                  <td class="text-left pipeline-option">Re-contracted: HK inno.N => Dr. Reddy's Laboratories</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Middle East and North Africa (MENA): 17 countries</td>
                  <td class="text-left pipeline-option">Re-contracted: HK inno.N => Tabuk Pharmaceutical</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Australia<br>New Zealand</td>
                  <td class="text-left pipeline-option">Re-contracted: HK inno.N => Southern XP</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>All countries except the above</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>P2X7 Receptor Antagonist</td>
                  <td>RQ-00466479<br>AK1780 [Asahi Kasei Pharma]<br>LY3857210 [Eli Lilly and Company]</td>
                  <td>Pain</td>
                  <td>- Asahi Kasei Pharma<br>- Eli Lilly and Company</td>
                  <td colspan="4"><div class="pipeline-arrow2">On going P2<br>(U.S., etc.)</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option">Contracted: Asahi Kasei Pharma => Eli Lilly and Company <a href="https://www.asahi-kasei.com/news/2020/e210129_2.html" target="_blank" rel="nofollow noopener">[Reference]</a><br>Diabetic neuropathic medicine, herpes virus infective neuropathic medicine. <a href="https://newswitch.jp/p/13022" target="_blank" rel="nofollow noopener">[Reference]</a></td>
                </tr>
                <tr>
                  <td>TRPV4 Antagonist</td>
                  <td>RQ-00317310</td>
                  <td>eye</td>
                  <td>-</td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option">Compounds created through collaborative research with Gifu Pharmaceutical University.</td>
                </tr>
                <tr>
                  <td rowspan="2"><a href="https://stock.ariafloat.com/raqualia/pipeline/trpm8-blocker.html">TRPM8 Blocker</a></td>
                  <td rowspan="2">RQ-00434739<br>XG2002 [Xgene]</td>
                  <td>Pain</td>
                  <td>Xgene Pharmaceutical</td>
                  <td colspan="3"><div class="pipeline-arrow2">On going P1<br>(Australia)</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global excluding Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Pain</td>
                  <td>-</td>
                  <td colspan="2"><div class="pipeline-arrow-prepared">On planning</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Selective Sodium Channel Blocker</td>
                  <td>-</td>
                  <td>Pain<br>Itch</td>
                  <td>-</td>
                  <td colspan="5">Clinical stage</td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Sodium Channel Blocker</td>
                  <td>RQ-00350215</td>
                  <td>Pain</td>
                  <td>Hisamitsu Pharmaceutical</td>
                  <td colspan="2"><div class="pipeline-arrow">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Specific Ion Channel</td>
                  <td>-</td>
                  <td>Gastrointestinal Tract</td>
                  <td>EA Pharma</td>
                  <td colspan="5">Undisclosed</td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>AI</td>
                  <td>-</td>
                  <td>Intractable/Rare Disease</td>
                  <td>SOCIUM<br>(Collaborative Research)</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>-</td>
                  <td>-</td>
                  <td>Intractable/Rare Disease</td>
                  <td>STAND Therapeutics<br>(Collaborative Research)</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Ion Channel</td>
                  <td>-</td>
                  <td>eye</td>
                  <td>D. Western Therapeutics Institute<br>(Collaborative Research)</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>mRNA</td>
                  <td>-</td>
                  <td>Cancer</td>
                  <td>Veritas In Silico<br>(Collaborative Research)</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Ion Channel</td>
                  <td>-</td>
                  <td>-</td>
                  <td>leadXpro<br>(Collaboration)</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td rowspan="3">5-HT4 Partial Agonist</td>
                  <td rowspan="2">RQ-00000010<br>VBX-3000 [Vetbiolix]</td>
                  <td>Gastroparesis<br>Functional dyspepsia<br>Chronic Constipation</td>
                  <td>-</td>
                  <td colspan="4"><div class="pipeline-arrow-prepared">On planning P2</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option">Mosapride's sales amount of peak tops is 21.2 billion yen (Japan)</td>
                </tr>
                <tr>
                  <td>Gut motility disorders: Dog/Cat</td>
                  <td>Vetbiolix</td>
                  <td colspan="5">PoC</td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>RQ-00000009<br>AAT-009 [AskAt]</td>
                  <td>Alzheimer's</td>
                  <td>AskAt<br>(Global)</td>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>5-HT2B Antagonist</td>
                  <td>RQ-00310941</td>
                  <td>IBS-D</td>
                  <td>-</td>
                  <td colspan="4"><div class="pipeline-arrow-prepared">On planning P2</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Motilin Receptor Agonist</td>
                  <td>RQ-00201894</td>
                  <td>Gastroparesis<br>Functional Dyspepsia<br>Post-Operative Ileus</td>
                  <td>-</td>
                  <td colspan="3"><div class="pipeline-arrow-prepared">On planning P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td rowspan="3">Ghrelin Receptor Agonist</td>
                  <td rowspan="2">RQ-00000005<br>（Capromorelin）<br>AT-002 [Elanco]</td>
                  <td>Appetite Stimulation: Dog</td>
                  <td rowspan="2">Elanco Animal Health<br>(Global (Animal))</td>
                  <td colspan="8"><div class="pipeline-arrow-sale">Launch (October 2017)</div></td>
                  <td>USA</td>
                  <td rowspan="2" class="text-left pipeline-option">Product name (Dog): Entyce<br>Product name (Cat): Elura</td>
                </tr>
                <tr>
                  <td>Management of Weight Loss with CKD: Cat</td>
                  <td colspan="8"><div class="pipeline-arrow-sale">Launch</div></td>
                  <td>USA<br>France<br>Japan</td>
                </tr>
                <tr>
                  <td>RQ-00433412</td>
                  <td>Cancer-Related Anorexia/Cachexia Syndrome<br>SCI-associated Constipation</td>
                  <td>-</td>
                  <td colspan="2"><div class="pipeline-arrow">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td rowspan="8">EP4 Antagonist</td>
                  <td rowspan="6">RQ-00000007<br>（Grapiprant）<br>AAT-007 [AskAt]<br>AT-001 [Elanco]<br>IK-007 [Ikena]<br>RMX1002 [RMX]<br>3D1002 [3D Medicines]</td>
                  <td>Osteoarthritis: Dog</td>
                  <td>Elanco Animal Health<br>(Global (Animal))</td>
                  <td colspan="8"><div class="pipeline-arrow-sale">Launch (USA: 2017, Europe: 2019, Brazil, Japan: 2020)</div></td>
                  <td>USA<br>Europe<br>Brazil<br>Japan</td>
                  <td class="text-left pipeline-option">Product name: Galliprant</td>
                </tr>
                <tr>
                  <td>MSS Colorectal Cancer<br>(MSS-CRC)</td>
                  <td rowspan="5">AskAt<br>(Global (Excluding animal))</td>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Metastatic Inflammatory Breast Cancer<br>(IBC)</td>
                  <td colspan="3"><div class="pipeline-arrow">IIT</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Cancer</td>
                  <td colspan="3"><div class="pipeline-arrow">On going P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => Ningbo Tai Kang Medical Technology<br>Development: Ningbo NewBay Medical Technology</td>
                </tr>
                <tr>
                  <td rowspan="2">Pain</td>
                  <td colspan="4"><div class="pipeline-arrow-end">Completed P2a</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => RMX Biopharma (Merged with Haihe BioPharma)<br>Haihe => 3D Medicines</td>
                </tr>
                <tr>
                  <td rowspan="2">RQ-00000008<br>AAT-008 [AskAt]</td>
                  <td rowspan="2">Cancer</td>
                  <td rowspan="2">AskAt<br>(Global)</td>
                  <td colspan="2"><div class="pipeline-arrow-end">Completed</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td colspan="3"><div class="pipeline-arrow-prepared">In preparation P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => Ningbo NewBay Medical Technology</td>
                </tr>
                <tr>
                  <td rowspan="3">COX-2 Inhibitor</td>
                  <td rowspan="3">RQ-00317076<br>AAT-076 [AskAt]<br>RMX1001 [RMX]<br>3D1001 [3D Medicines]</td>
                  <td rowspan="2">Pain</td>
                  <td rowspan="3">AskAt<br>(Global)</td>
                  <td colspan="4"><div class="pipeline-arrow-end">Completed P2a</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td colspan="3"><div class="pipeline-arrow">On going P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => RMX Biopharma (Merged with Haihe BioPharma)<br>Haihe => 3D Medicines</td>
                </tr>
                <tr>
                  <td>Pain<br>(Animal)</td>
                  <td colspan="4"><div class="pipeline-arrow-prepared">In preparation Pilot Study</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => Velo-1</td>
                </tr>
                <tr>
                  <td rowspan="2">CB2 Receptor Agonist</td>
                  <td rowspan="2">RQ-00202730<br>AAT-730 [AskAt]<br>OCT461201 [OCT]</td>
                  <td>Pain</td>
                  <td rowspan="2">AskAt<br>(Global)</td>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>UK</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => Oxford Cannabinoid Technologies (OCT) (Global excluding Japan)</td>
                </tr>
                <tr>
                  <td>Pain<br>Neuronal Diseases</td>
                  <td colspan="2"><div class="pipeline-arrow-end">Completed</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td></td>
                </tr>
                <tr>
                  <td>Certain four compounds</td>
                  <td>-</td>
                  <td>-</td>
                  <td>Velovia Pharma<br>(Global (Animal))</td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Echinocandin antifungal<br>(Anidulafungin)</td>
                  <td>Anidulafungin</td>
                  <td>Candida Infections</td>
                  <td>-</td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option">US product name: Eraxis</td>
                </tr>
                <tr>
                  <td>Glycopeptide anti-MRSA antibiotic<br>(Dalbavancin)</td>
                  <td>Dalbavancin</td>
                  <td>MRSA Infections</td>
                  <td>-</td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option">US product name: Dalvance</td>
                </tr>
                <tr>
                  <td rowspan="3">Ion Channel</td>
                  <td>-</td>
                  <td>-</td>
                  <td>-</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>-</td>
                  <td>-</td>
                  <td>-</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>-</td>
                  <td>-</td>
                  <td>-</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Other Contracts</h2>
          <p>Updated on 4 25, 2023</p>
          <div class="scrollbooster-viewport-contract-other">
            <table class="table-simple table-contract-other scrollbooster-viewport-content-contract-other">
              <colgroup>
                <col span="1" style="width: 120px;">
                <col span="1" style="width: 500px;">
                <col span="1" style="width: 110px;">
              </colgroup>
              <thead>
                <tr>
                  <th>Contractor</th>
                  <th>Contract contents</th>
                  <th>Remarks</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>H. Lundbeck A/S<br>(Denmark)</td>
                  <td>RaQualia Grants Patent License to H. Lundbeck</td>
                  <td></td>
                </tr>
                <tr>
                  <td>Shire AG<br>(Swiss)</td>
                  <td>RaQualia Grants a Non-Exclusive Patent License to Shire AG For the Use of Ghrelin Receptor Agonist</td>
                  <td></td>
                </tr>
                <tr>
                  <td>-</td>
                  <td>RaQualia Pharma Joins DeNA & DeNA Life Science AI-Powered Drug Discovery Research Collaboration</td>
                  <td><a href="https://www.raqualia.com/en/news/ir/irnews_en2795841983946995929/main/0/link/f13edde83fd8bb9183b935ea829416f8.pdf" target="_blank" rel="nofollow noopener">Press release</a></td>
                </tr>
                <tr>
                  <td>leadXpro AG</td>
                  <td>Collaboration to Accelerate Drug Discovery on Intractable Membrane Protein Targets</td>
                  <td><a href="https://www.raqualia.com/en/news/ir/ir-1879253146700030551/main/0/link/Raqualia_LeadXpro_2.pdf" target="_blank" rel="nofollow noopener">Press release</a></td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">University Collaborative Research</h2>
          <p>Updated on 2 14, 2023</p>
          <a href="http://www.riem.nagoya-u.ac.jp/4/rcrc/" target="_blank" rel="nofollow noopener">RaQualia Pharma Industry-Academia Collaborative Research Center</a>
          <br><br>
          <div class="scrollbooster-viewport-university">
            <table class="table-simple table-university scrollbooster-viewport-content-university">
              <colgroup>
                <col span="1" style="width: 110px;">
                <col span="1" style="width: 250px;">
                <col span="1" style="width: 300px;">
                <col span="1" style="width: 200px;">
              </colgroup>
              <thead>
                <tr>
                  <th>University</th>
                  <th>Department</th>
                  <th>Research theme</th>
                  <th>Remarks</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>Gifu Pharmaceutical University</td>
                  <td>Molecular Pharmacology, Department of Biofunctional Evaluation</td>
                  <td>Evaluation of efficacy of a specific compound on retinal vein occlusion (RVO)</td>
                  <td></td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">TMRC (subsidiary) Pipeline</h2>
          <p>Updated on 11 13, 2024</p>
          <div class="pipeline-arrow-example-en">
            <div class="pipeline-arrow-end-legend-en">Completed</div>
            <div class="pipeline-arrow-prepared-legend-en">On planning</div>
            <div class="pipeline-arrow-legend-en">On going</div><div class="pipeline-arrow-example-clearboth"></div>
            <div class="pipeline-arrow-sale-legend-en">Launch</div>
            <div class="pipeline-arrow-plan-legend-en">Plan</div>
            <div style="clear: both;"></div>
          </div>
          <div class="scrollbooster-viewport-pipeline">
            <table class="table-simple table-pipeline scrollbooster-viewport-content-pipeline">
              <colgroup>
                <col span="1" style="width: 140px;">
                <col span="1" style="width: 117px;">
                <col span="1" style="width: 135px;">
                <col span="1" style="width: 110px;">
                <col span="8" style="width: 62px;">
                <col span="1" style="width: 75px;">
                <col span="1" style="width: 255px;">
              </colgroup>
              <thead>
                <tr>
                  <th rowspan="2">Program</th>
                  <th rowspan="2">Compound code<br>(Generic name)</th>
                  <th rowspan="2">Indication</th>
                  <th rowspan="2">Partnered party</th>
                  <th rowspan="2">Discovery</th>
                  <th rowspan="2">Pre-Clin,</th>
                  <th colspan="3">Clinical Trial</th>
                  <th rowspan="2">NDA</th>
                  <th rowspan="2">Approval</th>
                  <th rowspan="2">Launch</th>
                  <th rowspan="2">Territory</th>
                  <th rowspan="2">Remarks</th>
                </tr>
                <tr style="font-size: 0.9em;">
                  <th>Phase 1</th>
                  <th>Phase 2</th>
                  <th>Phase 3</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="5">TM-411</td>
                  <td rowspan="5">TM-411<br>(Tamibarotene)<br>SY-1425 [Syros Pharmaceuticals]<br>OP-09 [Ohara Pharmaceutical]</td>
                  <td>Newly Diagnosed HR-MDS</td>
                  <td>Syros Pharmaceuticals</td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option">Combination with azacitidine. <a href="https://ir.syros.com/press-releases/detail/205/syros-presents-new-data-from-phase-2-clinical-trial-of" target="_blank" rel="nofollow noopener">Reference</a>.</td>
                </tr>
                <tr>
                  <td>Neuroblastoma<br>(NB)</td>
                  <td>Ohara Pharmaceutical</td>
                  <td colspan="3"><div class="pipeline-arrow">On going P1/2</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Pancreatic Cancer<br>(PC)</td>
                  <td>IIT<br>(Nagoya University)</td>
                  <td colspan="3"><div class="pipeline-arrow">On going P1/2</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Acute promyelocytic leukemia<br>(APL)</td>
                  <td>Toko Pharmaceutical Industrial</td>
                  <td colspan="6"><div class="pipeline-arrow">NDA</div></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Neutropenia<br>(NP)</td>
                  <td>-</td>
                  <td colspan="2"><div class="pipeline-arrow-end">Completed</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">TMRC (subsidiary) Pipeline</h2>
          <p>Updated on 2 14, 2024</p>
          <div class="pipeline-arrow-example-en">
            <div class="pipeline-arrow-end-legend-en">Completed</div>
            <div class="pipeline-arrow-prepared-legend-en">On planning</div>
            <div class="pipeline-arrow-legend-en">On going</div><div class="pipeline-arrow-example-clearboth"></div>
            <div class="pipeline-arrow-sale-legend-en">Launch</div>
            <div class="pipeline-arrow-plan-legend-en">Plan</div>
            <div style="clear: both;"></div>
          </div>
          <div class="scrollbooster-viewport-pipeline">
            <table class="table-simple table-pipeline scrollbooster-viewport-content-pipeline">
              <colgroup>
                <col span="1" style="width: 140px;">
                <col span="1" style="width: 117px;">
                <col span="1" style="width: 135px;">
                <col span="1" style="width: 110px;">
                <col span="8" style="width: 62px;">
                <col span="1" style="width: 75px;">
                <col span="1" style="width: 255px;">
              </colgroup>
              <thead>
                <tr>
                  <th rowspan="2">Program</th>
                  <th rowspan="2">Compound code<br>(Generic name)</th>
                  <th rowspan="2">Indication</th>
                  <th rowspan="2">Partnered party</th>
                  <th rowspan="2">Discovery</th>
                  <th rowspan="2">Pre-Clin,</th>
                  <th colspan="3">Clinical Trial</th>
                  <th rowspan="2">NDA</th>
                  <th rowspan="2">Approval</th>
                  <th rowspan="2">Launch</th>
                  <th rowspan="2">Territory</th>
                  <th rowspan="2">Remarks</th>
                </tr>
                <tr style="font-size: 0.9em;">
                  <th>Phase 1</th>
                  <th>Phase 2</th>
                  <th>Phase 3</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>IRAK-M</td>
                  <td>FIM-001</td>
                  <td>Non-small cell lung cancer<br>Pancreatic cancer<br>(Cancer immunity) etc.</td>
                  <td>-</td>
                  <td colspan="2"><div class="pipeline-arrow">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>TRIB1</td>
                  <td>-</td>
                  <td>Oncology</td>
                  <td>-</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Early stage project</td>
                  <td>-</td>
                  <td>Oncology</td>
                  <td>-</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>-</td>
                  <td>-</td>
                  <td>Oncology</td>
                  <td>Astellas Pharma</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>-</td>
                  <td>-</td>
                  <td>Oncology</td>
                  <td>Astellas Pharma</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Subsidiary</h2>
          <p>Updated on 2 14, 2024</p>
          <table class="table-simple table-subsidiary">
            <colgroup>
              <col span="1">
            </colgroup>
            <thead>
              <tr>
                <th>Company name</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td><a href="http://www.tmrc.co.jp/english/index.html" target="_blank" rel="nofollow noopener">TMRC Co., Ltd.</a></td>
              </tr>
              <tr>
                <td><a href="https://www.fimecs.com/" target="_blank" rel="nofollow noopener">FIMECS, Inc.</a></td>
              </tr>
            </tbody>
          </table>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 1rem; padding-bottom: 1rem;">
        <div class="container" style="max-width: 700px;">
          <p>Because of the personal survey, there are cases where the information on this site is "different from the fact" due to business content change or misunderstanding etc.<br>Therefore, please do not use for investment judgment. Also, this site is not intended to solicit investment.</p>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 1rem; padding-bottom: 1rem;">
        <div class="container">
          <!-- Google AdSense -->
          <div id="adsense" style="text-align: center;">
            <h6>Advertisements</h6>
            <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
            <!-- レスポンシブ広告 -->
            <ins class="adsbygoogle"
                 style="display:block"
                 data-ad-client="ca-pub-6825342955400774"
                 data-ad-slot="1464182490"
                 data-ad-format="auto"
                 data-full-width-responsive="true"></ins>
            <script>
            (adsbygoogle = window.adsbygoogle || []).push({});
            </script>
          </div>
        </div>
      </section>
    </main>
    <footer class="text-muted" style="background-color: #F2F2F2;">
      <div class="container">
        <p class="float-right">
          <a class="none-a" href="#top">Page top</a>
        </p>
        <p><a class="none-toppage" href="https://stock.ariafloat.com/">&copy; Ariafloat Stock.</a>
        </p>
      </div>
    </footer>
    <script src="../../js/vendor/modernizr-3.5.0.min.js"></script>
    <script src="https://code.jquery.com/jquery-3.2.1.min.js" integrity="sha256-hwg4gsxgFZhOsEEamdOYGBf13FyQuiTwlAQgxVSNgt4=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.3/umd/popper.min.js" integrity="sha384-vFJXuSJphROIrBnz7yo7oB41mKfc8JzQZiCq4NCceLEaO4IHwicKwpJf9c9IpFgh" crossorigin="anonymous"></script>
    <script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/js/bootstrap.min.js" integrity="sha384-alpBpkh1PFOepccYVYDB4do5UnbKysX5WZXm3XxPqe5iKTfUKjNkCk9SaVuEZflJ" crossorigin="anonymous"></script>
    <script src="../../js/plugins.js"></script>
    <script src="../../js/main.js"></script>
    <script src="../js/responsive.js"></script>
  </body>
</html>
